Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Schwab Fundamental US Large Company Index ETF
FNDX
|
+$8.54B |
| 2 |
Vanguard Mortgage-Backed Securities ETF
VMBS
|
+$6.22B |
| 3 |
Schwab US Large- Cap ETF
SCHX
|
+$6.12B |
| 4 |
Schwab Fundamental US Small Company Index ETF
FNDA
|
+$5.39B |
| 5 |
Schwab 5-10 Year Corporate Bond ETF
SCHI
|
+$5.01B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Texas Instruments
TXN
|
+$367M |
| 2 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$335M |
| 3 |
Diageo
DEO
|
+$297M |
| 4 |
Medtronic
MDT
|
+$259M |
| 5 |
GE Aerospace
GE
|
+$222M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.36% |
| 2 | Financials | 10.66% |
| 3 | Healthcare | 9.68% |
| 4 | Consumer Discretionary | 8.35% |
| 5 | Industrials | 7.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1876
Beam Therapeutics
BEAM
$2.63B
| $13.9M | ﹤0.01% |
593,266
+13,994
| +2% | +$344K |
|
1877
Flex
FLEX
$41.7B
| $13.8M | ﹤0.01% |
469,507
-1,521
| -0.3% | -$45.5K |
|
1878
NovoCure
NVCR
$1.73B
| $13.8M | ﹤0.01% |
808,104
+277,049
| +52% | +$4.87M |
|
1879
Dole
DOLE
$1.35B
| $13.8M | ﹤0.01% |
1,128,428
-176,837
| -14% | -$2.15M |
|
1880
National Bank Holdings
NBHC
$1.92B
| $13.8M | ﹤0.01% |
353,278
+10,136
| +3% | +$359K |
|
|
RC
1881
Ready Capital
RC
$258M
| $13.7M | ﹤0.01% |
1,672,917
+205,629
| +14% | +$1.75M |
|
1882
Innoviva
INVA
$1.55B
| $13.6M | ﹤0.01% |
831,062
-97,601
| -11% | -$1.51M |
|
1883
TriCo Bancshares
TCBK
$1.84B
| $13.6M | ﹤0.01% |
343,771
-16,431
| -5% | -$594K |
|
1884
State Street SPDR Portfolio S&P 500 Value ETF
SPYV
$36.1B
| $13.5M | ﹤0.01% |
277,727
-22,466
| -7% | -$1.1M |
|
1885
Sotera Health
SHC
$5.09B
| $13.5M | ﹤0.01% |
1,140,003
-3,843
| -0.3% | -$43.9K |
|
1886
MarineMax
HZO
$759M
| $13.5M | ﹤0.01% |
416,322
-73,102
| -15% | -$2.14M |
|
1887
Argan
AGX
$8B
| $13.5M | ﹤0.01% |
183,960
+506
| +0.3% | +$33.2K |
|
1888
CRA International
CRAI
$1.16B
| $13.5M | ﹤0.01% |
78,120
-7,061
| -8% | -$1.14M |
|
1889
ProPetro Holding
PUMP
$1.36B
| $13.4M | ﹤0.01% |
1,550,607
-219,410
| -12% | -$1.96M |
|
1890
Syndax Pharmaceuticals
SNDX
$1.69B
| $13.4M | ﹤0.01% |
654,489
+19,282
| +3% | +$404K |
|
1891
OceanFirst Financial
OCFC
$1.68B
| $13.4M | ﹤0.01% |
844,115
-53,668
| -6% | -$811K |
|
1892
RxSight
RXST
$249M
| $13.4M | ﹤0.01% |
222,822
+29,078
| +15% | +$1.66M |
|
1893
Magnite
MGNI
$2.76B
| $13.4M | ﹤0.01% |
1,006,448
+623
| +0.1% | +$6.81K |
|
1894
BrightView Holdings
BV
$1.22B
| $13.4M | ﹤0.01% |
1,004,432
-62,609
| -6% | -$798K |
|
1895
Arlo Technologies
ARLO
$1.6B
| $13.3M | ﹤0.01% |
1,022,092
+15,019
| +1% | +$187K |
|
1896
Rocket Companies
RKT
$36.5B
| $13.3M | ﹤0.01% |
968,401
+119,676
| +14% | +$1.62M |
|
1897
Ecovyst
ECVT
$1.32B
| $13.2M | ﹤0.01% |
1,473,980
+44,437
| +3% | +$430K |
|
1898
CAVA Group
CAVA
$7.6B
| $13.2M | ﹤0.01% |
142,257
+7,189
| +5% | +$555K |
|
1899
John B. Sanfilippo & Son
JBSS
$967M
| $13.2M | ﹤0.01% |
135,763
+2,479
| +2% | +$248K |
|
1900
Levi Strauss
LEVI
$9.44B
| $13.2M | ﹤0.01% |
683,415
+97,824
| +17% | +$2.14M |
|
Similar funds
Charles Schwab's Q2 2024 Portfolio in Review
As of Q2 2024, Charles Schwab held 3,738 positions worth $525B, up 21% from $433B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Charles Schwab deployed $84.3B of net new capital in Q2 2024, opening 263 new positions and adding to 2,391 existing holdings. Its largest new stake was Schwab Fundamental US Small Company Index ETF: 195,294,508 shares worth $5.36B.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 23% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Texas Instruments, an estimated $367M trimmed.
- Charles Schwab's largest Q2 2024 buy was Schwab Fundamental US Small Company Index ETF: 195,294,508 shares worth $5.36B.
- Charles Schwab added most to Schwab Fundamental US Large Company Index ETF in Q2 2024, an estimated $8.54B increase.
- Charles Schwab's biggest Q2 2024 reduction was Texas Instruments, cutting an estimated $367M.
- Charles Schwab fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $335M.
- Charles Schwab's ten largest holdings make up 21% of its $525B portfolio in Q2 2024.
- Charles Schwab opened 263 new positions and closed 116 in Q2 2024.
- Charles Schwab's portfolio value rose 21% quarter-over-quarter to $525B.
Based on Charles Schwab's 13F filing for Q2 2024, filed 12 Aug 2024.